GENEVA--(Marketwire - August 20, 2012) -
Addex Therapeutics / Addex Therapeutics First Half 2012 Financial Results
Next Wednesday.
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Addex Therapeutics (SIX: ADXN), a leading
biopharmaceutical company pioneering allosteric modulation-based drug
discovery
and development will discuss its first half 2012 financial results,
provide a
business update and review its pipeline during a teleconference and
webcast for
investors, analysts and the media on Wednesday, August 22 at 16:00 CET
(15:00
GMT/10:00 EST) .
Title: Addex Half-Year 2012 Financial Results
Conference
Call
Date: August 22(nd), 2012
Time: 16:00 CET (15:00 GMT/10:00 EST)
To participate, please listen to the webcast or call one of the following
telephone numbers. RSVP is not necessary.
Dial-in numbers:
+41 91 610 56 00 (Europe)
+44 203 059 58 62 (UK)
+1 866 291 4166 (USA)
The live webcast, slides, webcast replay and transcript, will be available
at
www.addextherapeutics.com.
Addex Therapeutics (www.addextherapeutics.com) discovers and
develops an
emerging class of small molecule drugs, called allosteric modulators, which
have
the potential to be more specific and confer significant therapeutic
advantages
over conventional "orthosteric" small molecule or biological drugs. The
Company
uses its proprietary discovery platform to address receptors and other
proteins
that are recognized as attractive targets for modulation of important
diseases
with unmet medical needs. The Company's two lead products are being
investigated
in Phase 2 clinical testing: dipraglurant (ADX48621, an mGluR5
negative
allosteric modulator or NAM) is being developed by Addex to treat
Parkinson's
disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2
positive
allosteric modulator or PAM) is being developed by our partner
Janssen
Pharmaceuticals Inc. to treat schizophrenia and anxiety seen in
patients
suffering from major depressive disorder. Addex also is advancing
several
preclinical programs including: GABA-BR PAM for overactive bladder,
pain and
other disorders; mGluR4 PAM for Parkinson's, MS, anxiety and other
diseases;
GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer's
disease
and depression. In addition, Addex has discovery programs to identify
allosteric
modulators of: receptor tyrosine kinase (RTK) superfamily, including
TrkB PAM
for treating neurodegenerative diseases (e.g. Alzheimer's,
Parkinson's and
Huntington's diseases); and TNF receptor superfamily, including TNFR1
NAM for
inflammation (e.g. rheumatoid arthritis) and other diseases.
Disclaimer: The foregoing release may contain forward-looking statements
that
can be identified by terminology such as "not approvable",
"continue",
"believes", "believe", "will", "remained open to exploring", "would",
"could",
or similar expressions, or by express or implied discussions regarding
Addex
Therapeutics, formerly known as, Addex Pharmaceuticals, its
business, the
potential approval of its products by regulatory authorities, or
regarding
potential future revenues from such products. Such forward-looking
statements
reflect the current views of Addex Therapeutics regarding future events,
future
economic performance or prospects, and, by their very nature, involve
inherent
risks and uncertainties, both general and specific, whether known or
unknown,
and/or any other factor that may materially differ from the plans,
objectives,
expectations, estimates and intentions expressed or implied in such
forward-looking statements. Such may in particular cause actual results
with allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or
other
therapeutic targets to be materially different from any future
results,
performance or achievements expressed or implied by such statements.
There can
be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5,
GABABR,
GLP1R, TNFR1, TrkB or other therapeutics targets will be approved for
sale in
any market or by any regulatory authority. Nor can there be any guarantee
that
allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1,
TrkB or
other therapeutic targets will achieve any particular levels of revenue (if
any)
in the future. In particular, management's expectations regarding
allosteric
modulators of mGluR2, mGluR4, mGluR5, GABABR, GLP1R, TNFR1, TrkB or
other
therapeutic targets could be affected by, among other things, unexpected
actions
by our partners, unexpected regulatory actions or delays or
government
regulation generally; unexpected clinical trial results, including
unexpected
new clinical data and unexpected additional analysis of existing clinical
data;
competition in general; government, industry and general public
pricing
pressures; the company's ability to obtain or maintain patent or
other
proprietary intellectual property protection. Should one or more of these
risks
or uncertainties materialize, or should underlying assumptions prove
incorrect,
actual results may vary materially from those anticipated, believed,
estimated
or expected. Addex Therapeutics is providing the information in this
press
release as of this date and does not undertake any obligation to
update any
forward-looking statements contained in this press release as a result
of new
information, future events or otherwise, except as may be required by
applicable
laws.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Addex Therapeutics via Thomson Reuters ONE
[HUG#1634759]
